Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PCS

Executive Summary

CVS "does not intend to purchase PCS Health Systems from Rite Aid," the drug store chain says following reports that it was one of two bidders for the pharmacy benefit management company. CVS noted that it has a "broad and deep strategic alliance with Merck-Medco" and has its own PBM, PharmaCare. Rite Aid paid $1.5 bil. for PCS in January 1999, but is seeking to sell the subsidiary to help pay off debt (1"The Pink Sheet" Oct. 25, 1999, p. 13)

You may also be interested in...



Rite Aid Hopes For Greener Pastures After Cutting Grass

Rite Aid will be operating under a one-year turnaround deadline following the departure of CEO Martin Grass and the infusion of $300 mil. from Leonard Green & Partners.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

UsernamePublicRestriction

Register

LL029263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel